TerminatedPhase 2NCT02452970

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
EpicentRx, Inc.
Principal Investigator
Ana De Jesus Acosta, MD
Johns Hopkins School of Medicine
Intervention
RRx-001(drug)
Enrollment
4 enrolled
Eligibility
18 years · All sexes
Timeline
20152016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02452970 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials